フルコナゾール (Synonyms: Fluconazole; UK-49858)

Name: Fluconazole
Brand: MedChemExpress
SKU: HY-B0101
Rating: 5.0 (21 reviews)

製品番号: HY-B0101 純度: 99.74%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Fluconazole (UK-49858) is a triazole antifungal agent with excellent activities against a broad range of fungi, especially against Candida albicans. Fluconazole inhibits C. albicans and Candida kefyr with IC₉₉s range from 0.20 μg/mL to 0.39 μg/mL.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 86386-73-4

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 72	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 72	在庫あり	Estimated Time of Arrival: December 31
Solid
100 mg	$66	在庫あり	Estimated Time of Arrival: December 31
500 mg	$92	在庫あり	Estimated Time of Arrival: December 31
1 g		お問い合わせ
5 g		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 21 publication(s) in Google Scholar

Other Forms of Fluconazole:

Fluconazole-d₄ 在庫あり
Fluconazole (Standard) 在庫あり
Fluconazole-¹³C₂,¹⁵N お問い合わせ
Fluconazole hydrate お問い合わせ
Fluconazole mesylate お問い合わせ

顧客検証

In Vivo Efficacy Study

Microbiological Assay

Histological Imaging/Staining

: Fluconazole purchased from MedChemExpress. Usage Cited in: Sci Adv. 2021 May 7;7(19):eabe5171. [Abstract]; Fungal burden of DSS (2.5%)–treated Cbl^f/fCD11c^Cre/+ and c-Cbl^f/f mice (n = 4 to 7 mice group in each experiment), which were pretreated with or without fluconazole (0.5 mg/mL, 15 days) in drinking water.

: Fluconazole purchased from MedChemExpress. Usage Cited in: Sci Adv. 2021 May 7;7(19):eabe5171. [Abstract]; Weight loss of DSS (2.5%)–treated Cbl^f/fCD11c^Cre/+ and c-Cbl^f/f mice (n = 4 to 7 mice group in each experiment), which were pretreated with or without fluconazole (0.5 mg/mL, 15 days) in drinking water.

: Fluconazole purchased from MedChemExpress. Usage Cited in: Sci Adv. 2021 May 7;7(19):eabe5171. [Abstract]; Colon length of DSS (2.5%)–treated Cbl^f/fCD11c^Cre/+ and c-Cbl^f/f mice (n = 4 to 7 mice group in each experiment), which were pretreated with or without fluconazole (0.5 mg/mL, 15 days) in drinking water.

: Fluconazole purchased from MedChemExpress. Usage Cited in: Sci Adv. 2021 May 7;7(19):eabe5171. [Abstract]; Histological analysis of DSS (2.5%)–treated Cbl^f/fCD11c^Cre/+ and c-Cbl^f/f mice (n = 4 to 7 mice group in each experiment), which were pretreated with or without fluconazole (0.5 mg/mL, 15 days) in drinking water.

: Fluconazole purchased from MedChemExpress. Usage Cited in: Microb Biotechnol. 2022 Feb;15(2):482-498. [Abstract]; Candida albicans (SC5314) was placed in YPD medium and serially diluted with fluconazole, panatinib, or both. OD600 values were measured every 15 minutes at 30°C, and FICI values were calculated according to the CLSI Broth Microdilution Reference Guide (M38-A)

Antibiotic アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

Cellular Effect

Cell Line	Type	Value	Description	References
16HBE14o-	CC₅₀	>1000 6 Compound: FLC	Cytotoxicity against human 16HBE by MTS assay Cytotoxicity against human 16HBE by MTS assay	[PMID: 34998904]
16HBE14o-	CC₅₀	> 1000 6 Compound: FLC	Cytotoxicity against human 16HBE by MTS assay Cytotoxicity against human 16HBE by MTS assay	[PMID: 34998904]
A549	EC₅₀	>62.5 6 Compound: FLC	Toxicity in human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin dye based assay Toxicity in human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin dye based assay	[PMID: 28395217]
A549	IC₅₀	>50 3 Compound: 1; FLC, FCZ	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay	[PMID: 34749201]
A549	IC₅₀	>50 3 Compound: FLC	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35255313]
A549	IC₅₀	>30 3 Compound: FLC	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 34388384]
A549	EC₅₀	> 62.5 6 Compound: FLC	Toxicity in human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin dye based assay Toxicity in human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin dye based assay	[PMID: 28395217]
A549	IC₅₀	>100 6 Compound: FCZ	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 30318439]
BEAS-2B	EC₅₀	>62.5 6 Compound: FLC	Toxicity in human BEAS2B cells assessed as reduction in cell viability incubated for 24 hrs by resazurin dye based assay Toxicity in human BEAS2B cells assessed as reduction in cell viability incubated for 24 hrs by resazurin dye based assay	[PMID: 28395217]
A549	IC₅₀	> 100 6 Compound: FCZ	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 30318439]
A549	IC₅₀	> 30 3 Compound: FLC	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 34388384]
Caco-2	IC₅₀	>64 6 Compound: FLC	Cytotoxicity against human Caco-2 cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay Cytotoxicity against human Caco-2 cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay	[PMID: 37975824]
H9c2	IC₅₀	>100 6 Compound: FCZ	Cytotoxicity against rat H9c2 cells by MTT assay Cytotoxicity against rat H9c2 cells by MTT assay	[PMID: 30318439]
A549	IC₅₀	> 50 3 Compound: 1; FLC, FCZ	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay	[PMID: 34749201]
A549	IC₅₀	> 50 3 Compound: FLC	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35255313]
HEK293	IC₅₀	>250 3 Compound: Fluconazole	Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay	[PMID: 29626797]
BEAS-2B	EC₅₀	> 62.5 6 Compound: FLC	Toxicity in human BEAS2B cells assessed as reduction in cell viability incubated for 24 hrs by resazurin dye based assay Toxicity in human BEAS2B cells assessed as reduction in cell viability incubated for 24 hrs by resazurin dye based assay	[PMID: 28395217]
HEK-293T	IC₅₀	>50 3 Compound: 1; FLC, FCZ	Cytotoxicity against human HEK293T cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay Cytotoxicity against human HEK293T cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay	[PMID: 34749201]
HeLa	IC₅₀	>100 6 Compound: Fluconazole	Cytotoxicity against human HeLa cells after 48 hrs by SRB assay Cytotoxicity against human HeLa cells after 48 hrs by SRB assay	[PMID: 26848627]
HepG2	CC₅₀	>128 13 Compound: FLC	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by XTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by XTT assay	[PMID: 33335669]
HepG2	IC₅₀	>250 6 Compound: Fluconazole	Cytotoxicity against human HepG2 cells after 2 days by MTT assay Cytotoxicity against human HepG2 cells after 2 days by MTT assay	[PMID: 25740636]
HepG2	IC₅₀	>50 3 Compound: 1; FLC, FCZ	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay	[PMID: 34749201]
HepG2	IC₅₀	>300 3 Compound: FLU	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay	[PMID: 24953953]
HepG2	IC₅₀	>50 3 Compound: FLC	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35255313]
Caco-2	IC₅₀	> 64 6 Compound: FLC	Cytotoxicity against human Caco-2 cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay Cytotoxicity against human Caco-2 cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay	[PMID: 37975824]
HepG2	IC₅₀	>100 6 Compound: FCZ	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 30318439]
HL-60	IC₅₀	11.6 3 Compound: Fluconazole	Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth by MTT assay	[PMID: 36336315]
HT-29	IC₅₀	>100 6 Compound: FCZ	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 30318439]
HUVEC	IC₅₀	>64 6 Compound: FLC	Cytotoxicity against human HUVEC cells assessed as inhibition on cell growth incubated for 24 hrs by CCK-8 assay Cytotoxicity against human HUVEC cells assessed as inhibition on cell growth incubated for 24 hrs by CCK-8 assay	[PMID: 35922963]
HUVEC	IC₅₀	9.177 6 Compound: FLC	Cytotoxicity against HUVEC cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay Cytotoxicity against HUVEC cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay	[PMID: 37975824]
HUVEC	IC₅₀	>40 3 Compound: FLC	Inhibition of HDAC in HUVEC using Boc-Lys(Ac)-AMC as substrate preincubated for 12 hrs followed by substrate addition and measured after 4 hrs by fluorimetry Inhibition of HDAC in HUVEC using Boc-Lys(Ac)-AMC as substrate preincubated for 12 hrs followed by substrate addition and measured after 4 hrs by fluorimetry	[PMID: 32347094]
K562	CC₅₀	385.2 3 Compound: 5, fluconazole	Cytotoxicity against human K562 cells after assessed as reduction of cell viability 24 hrs by MTT assay Cytotoxicity against human K562 cells after assessed as reduction of cell viability 24 hrs by MTT assay	[PMID: 18529046]
K562	CC₅₀	385.2 3 Compound: 5	Cytotoxicity to reduce chronic myeloid leukemia K 562 cells Cytotoxicity to reduce chronic myeloid leukemia K 562 cells	[PMID: 15267229]
L6	IC₅₀	9.967 3 Compound: fluconazole	Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi Tulahuen C4 infected in rat L6 cells assessed as parasite growth inhibition after 96 hrs by colorimetric analysis Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi Tulahuen C4 infected in rat L6 cells assessed as parasite growth inhibition after 96 hrs by colorimetric analysis	[PMID: 25580906]
L6	IC₅₀	>294.1 3 Compound: fluconazole	Cytotoxicity against rat L6 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay Cytotoxicity against rat L6 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay	[PMID: 25580906]
LLC-PK1	IC₅₀	>10 6 Compound: FLU	Cytotoxicity against LLC-PK1 cells by neutral red method Cytotoxicity against LLC-PK1 cells by neutral red method	[PMID: 17181171]
MCF7	IC₅₀	>50 3 Compound: 1; FLC, FCZ	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay	[PMID: 34749201]
MCF7	IC₅₀	>50 3 Compound: FLC	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35255313]
MCF7	IC₅₀	>30 3 Compound: FLC	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 34388384]
MDA-MB-231	IC₅₀	19.21 3 Compound: Fluconazole	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay	[PMID: 36336315]
NIH3T3	IC₅₀	387 6 Compound: fluconazole	Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT colorimetric assay Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT colorimetric assay	[PMID: 18032039]
PBMC	CC₅₀	676.43 6 Compound: FLC	Cytotoxicity against PBMC (unknown origin) by MTT assay Cytotoxicity against PBMC (unknown origin) by MTT assay	[PMID: 34998904]
PBMC	IC₅₀	>16.32 3 Compound: Fluconazole	Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay	[PMID: 24485783]
PC-3	IC₅₀	16.49 3 Compound: Fluconazole	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by MTT assay	[PMID: 36336315]
Peritoneal macrophage cell	IC₅₀	>100 3 Compound: Fluconazole	Cytotoxicity against C57BL/6 mouse peritoneal macrophages assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against C57BL/6 mouse peritoneal macrophages assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 26276437]
RAW264.7	IC₅₀	>50 3 Compound: FLC	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35255313]
THLE-2	IC₅₀	>50 3 Compound: FLC	Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35255313]
H9c2	IC₅₀	> 100 6 Compound: FCZ	Cytotoxicity against rat H9c2 cells by MTT assay Cytotoxicity against rat H9c2 cells by MTT assay	[PMID: 30318439]
THLE-2	IC₅₀	>30 3 Compound: FLC	Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 34388384]
HEK-293T	IC₅₀	> 50 3 Compound: 1; FLC, FCZ	Cytotoxicity against human HEK293T cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay Cytotoxicity against human HEK293T cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay	[PMID: 34749201]
U-937	CC₅₀	328 3 Compound: 5, fluconazole	Cytotoxicity against human U937 cells assessed as reduction of cell viability after 24 hrs by MTT assay Cytotoxicity against human U937 cells assessed as reduction of cell viability after 24 hrs by MTT assay	[PMID: 18529046]
U-937	CC₅₀	316 3 Compound: 5	Cytotoxicity to reduce human histolytic lymphoma U937 cells Cytotoxicity to reduce human histolytic lymphoma U937 cells	[PMID: 15267229]
Vero	IC₅₀	>100 3 Compound: Fluconazole	Cytotoxicity against African green monkey Vero cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 26276437]
Vero	IC₅₀	>10 6 Compound: FLU	Cytotoxicity against Vero cells by neutral red method Cytotoxicity against Vero cells by neutral red method	[PMID: 17181171]
HEK293	IC₅₀	> 250 3 Compound: Fluconazole	Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay	[PMID: 29626797]
HL-60	IC₅₀	11.6 3 Compound: Fluconazole	Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth by MTT assay	[PMID: 36336315]
HT-29	IC₅₀	> 100 6 Compound: FCZ	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 30318439]
HUVEC	IC₅₀	9.177 6 Compound: FLC	Cytotoxicity against HUVEC cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay Cytotoxicity against HUVEC cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay	[PMID: 37975824]
HUVEC	IC₅₀	> 40 3 Compound: FLC	Inhibition of HDAC in HUVEC using Boc-Lys(Ac)-AMC as substrate preincubated for 12 hrs followed by substrate addition and measured after 4 hrs by fluorimetry Inhibition of HDAC in HUVEC using Boc-Lys(Ac)-AMC as substrate preincubated for 12 hrs followed by substrate addition and measured after 4 hrs by fluorimetry	[PMID: 32347094]
HUVEC	IC₅₀	> 64 6 Compound: FLC	Cytotoxicity against human HUVEC cells assessed as inhibition on cell growth incubated for 24 hrs by CCK-8 assay Cytotoxicity against human HUVEC cells assessed as inhibition on cell growth incubated for 24 hrs by CCK-8 assay	[PMID: 35922963]
HeLa	IC₅₀	> 100 6 Compound: Fluconazole	Cytotoxicity against human HeLa cells after 48 hrs by SRB assay Cytotoxicity against human HeLa cells after 48 hrs by SRB assay	[PMID: 26848627]
HepG2	CC₅₀	> 128 13 Compound: FLC	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by XTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by XTT assay	[PMID: 33335669]
HepG2	IC₅₀	> 100 6 Compound: FCZ	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 30318439]
HepG2	IC₅₀	> 250 6 Compound: Fluconazole	Cytotoxicity against human HepG2 cells after 2 days by MTT assay Cytotoxicity against human HepG2 cells after 2 days by MTT assay	[PMID: 25740636]
HepG2	IC₅₀	> 300 3 Compound: FLU	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay	[PMID: 24953953]
HepG2	IC₅₀	> 50 3 Compound: 1; FLC, FCZ	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay	[PMID: 34749201]
HepG2	IC₅₀	> 50 3 Compound: FLC	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35255313]
K562	CC₅₀	385.2 3 Compound: 5	Cytotoxicity to reduce chronic myeloid leukemia K 562 cells Cytotoxicity to reduce chronic myeloid leukemia K 562 cells	[PMID: 15267229]
K562	CC₅₀	385.2 3 Compound: 5, fluconazole	Cytotoxicity against human K562 cells after assessed as reduction of cell viability 24 hrs by MTT assay Cytotoxicity against human K562 cells after assessed as reduction of cell viability 24 hrs by MTT assay	[PMID: 18529046]
L6	IC₅₀	9.967 3 Compound: fluconazole	Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi Tulahuen C4 infected in rat L6 cells assessed as parasite growth inhibition after 96 hrs by colorimetric analysis Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi Tulahuen C4 infected in rat L6 cells assessed as parasite growth inhibition after 96 hrs by colorimetric analysis	[PMID: 25580906]
L6	IC₅₀	> 294.1 3 Compound: fluconazole	Cytotoxicity against rat L6 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay Cytotoxicity against rat L6 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay	[PMID: 25580906]
LLC-PK1	IC₅₀	> 10 6 Compound: FLU	Cytotoxicity against LLC-PK1 cells by neutral red method Cytotoxicity against LLC-PK1 cells by neutral red method	[PMID: 17181171]
MCF7	IC₅₀	> 30 3 Compound: FLC	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 34388384]
MCF7	IC₅₀	> 50 3 Compound: 1; FLC, FCZ	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 4 hrs by MTT assay	[PMID: 34749201]
MCF7	IC₅₀	> 50 3 Compound: FLC	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35255313]
MDA-MB-231	IC₅₀	19.21 3 Compound: Fluconazole	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay	[PMID: 36336315]
NIH3T3	IC₅₀	387 6 Compound: fluconazole	Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT colorimetric assay Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT colorimetric assay	[PMID: 18032039]
PBMC	CC₅₀	676.43 6 Compound: FLC	Cytotoxicity against PBMC (unknown origin) by MTT assay Cytotoxicity against PBMC (unknown origin) by MTT assay	[PMID: 34998904]
PBMC	IC₅₀	> 16.32 3 Compound: Fluconazole	Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay	[PMID: 24485783]
PC-3	IC₅₀	16.49 3 Compound: Fluconazole	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by MTT assay	[PMID: 36336315]
Peritoneal macrophage cell	IC₅₀	> 100 3 Compound: Fluconazole	Cytotoxicity against C57BL/6 mouse peritoneal macrophages assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against C57BL/6 mouse peritoneal macrophages assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 26276437]
RAW264.7	IC₅₀	> 50 3 Compound: FLC	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35255313]
THLE-2	IC₅₀	> 30 3 Compound: FLC	Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 34388384]
THLE-2	IC₅₀	> 50 3 Compound: FLC	Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35255313]
U-937	CC₅₀	316 3 Compound: 5	Cytotoxicity to reduce human histolytic lymphoma U937 cells Cytotoxicity to reduce human histolytic lymphoma U937 cells	[PMID: 15267229]
U-937	CC₅₀	328 3 Compound: 5, fluconazole	Cytotoxicity against human U937 cells assessed as reduction of cell viability after 24 hrs by MTT assay Cytotoxicity against human U937 cells assessed as reduction of cell viability after 24 hrs by MTT assay	[PMID: 18529046]
Vero	IC₅₀	> 100 3 Compound: Fluconazole	Cytotoxicity against African green monkey Vero cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 26276437]
Vero	IC₅₀	> 10 6 Compound: FLU	Cytotoxicity against Vero cells by neutral red method Cytotoxicity against Vero cells by neutral red method	[PMID: 17181171]

体外実験

Fluconazole inhibits 4 species ofAspergillus fumigatus with the IC₅₀s of 23.9-43.5 μg/mL. Fluconazole (0.20 μg/mL) inhibits significantly the mycelial-phase growth and germ tube elongation of C. albicans in a medium supplemented with serum^[1].
Fluconazole is a triazole antifungal agent that has been available for the treatment of infections due to Candida, Cryptococcus. The MIC₉₀ is highest for C. krusei (MIC ≥ 64 μg/mL) and C. glabrata (MIC, 32 μg/mL) and is ≤2 μg/mL for C. albicans (0.5 μg/mL), C. parapsilosis (2 μg/mL), C. tropicalis (2 μg/mL), C. lusitaniae (2 μg/mL), and C. kefyr (0.5 μg/mL)^[2].
Fluconazole (0.1-50.0 μg/mL) damages the fungal cells and reduces their viability^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:	C.albicans yeast cells (strain ATCC 26310 and strain TW)
Concentration:	0.1, 0.5, 5.0, 50.0 μg/mL
Incubation Time:	24 hours
Result:	The MICs against both strains were 0.5 μg/mL.

体内実験

Fluconazole ( 0, 0.5, 1, 2.5, 5, 7.5, and 10 mg/kg; administered intraperitoneally (i.p.) as a single dose) results in a 50% reduction in fungal densities (ED50) of 4.87 mg/kg in a murine model of systemic candidiasis^[4]. Fluconazole exhibits terminal elimination half-life of 2.4 h) following i.p. administration.The terminal half-life does not change with the dose of fluconazole administered^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female NYLAR mice (weight, 18 to 20 g; infected intravenously with C. albicans blastoconidia)^[4]
Dosage:	5, 10, 15 and 20 mg/kg (Pharmacokinetic Analysis)
Administration:	Given i.p. as a single dose
Result:	T_1/2=2.4 h

分子量

306.27

分子式

C₁₃H₁₂F₂N₆O

CAS 番号

86386-73-4

Appearance

Solid

Color

White to off-white

SMILES

FC1=CC=C(C(O)(CN2C=NC=N2)CN3C=NC=N3)C(F)=C1

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : ≥ 100 mg/mL (326.51 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 2 mg/mL (6.53 mM; Need ultrasonic)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.2651 mL	16.3255 mL	32.6509 mL
5 mM	0.6530 mL	3.2651 mL	6.5302 mL
10 mM	0.3265 mL	1.6325 mL	3.2651 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 2 mg/mL (6.53 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.74%

Select Batch:

データシート (283 KB) SDS (558 KB)

COA (254 KB) RP-HPLC (276 KB)

取扱説明書 (2659 KB)

参考文献

[1]. H Yamaguchi, et al. [In vitro activity of fluconazole, a novel bistriazole antifungal agent]. Jpn J Antibiot. 1989 Jan;42(1):1-16. [Content Brief]

[2]. M A Pfaller, et al. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev. 2006 Apr;19(2):435-47. [Content Brief]

[3]. P G Sohnle, et al. Effect of fluconazole on viability of Candida albicans over extended periods of time. Antimicrob Agents Chemother. 1996 Nov;40(11):2622-5. [Content Brief]

[4]. A Louie, et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother. 1998 May;42(5):1105-9. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	3.2651 mL	16.3255 mL	32.6509 mL	81.6273 mL
H₂O / DMSO	5 mM	0.6530 mL	3.2651 mL	6.5302 mL	16.3255 mL
DMSO	10 mM	0.3265 mL	1.6325 mL	3.2651 mL	8.1627 mL
	15 mM	0.2177 mL	1.0884 mL	2.1767 mL	5.4418 mL
	20 mM	0.1633 mL	0.8163 mL	1.6325 mL	4.0814 mL
	25 mM	0.1306 mL	0.6530 mL	1.3060 mL	3.2651 mL
	30 mM	0.1088 mL	0.5442 mL	1.0884 mL	2.7209 mL
	40 mM	0.0816 mL	0.4081 mL	0.8163 mL	2.0407 mL
	50 mM	0.0653 mL	0.3265 mL	0.6530 mL	1.6325 mL
	60 mM	0.0544 mL	0.2721 mL	0.5442 mL	1.3605 mL
	80 mM	0.0408 mL	0.2041 mL	0.4081 mL	1.0203 mL
	100 mM	0.0327 mL	0.1633 mL	0.3265 mL	0.8163 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Fluconazole Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

フルコナゾール (Synonyms: Fluconazole; UK-49858)

カスタマーレビュー

Other Forms of Fluconazole:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Antibiotic アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Fluconazole Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

フルコナゾール (Synonyms: Fluconazole; UK-49858)

カスタマーレビュー

Other Forms of Fluconazole:

フルコナゾール 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Antibiotic アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

フルコナゾール 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Fluconazole Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report

フルコナゾール関連抗体

フルコナゾール関連抗体